<DOC>
	<DOCNO>NCT00211133</DOCNO>
	<brief_summary>The purpose study evaluate impact survival quality life maintain hemoglobin range 12 14 g/dL use epoetin alfa placebo patient start chemotherapy metastatic breast cancer first time .</brief_summary>
	<brief_title>A Study Evaluate Impact Maintaining Hemoglobin Levels Using Epoetin Alfa Patients With Metastatic Breast Cancer Receiving Chemotherapy</brief_title>
	<detailed_description>Cancer patient often experience anemia due disease , chemotherapy . Quality life also affect , due part fatigue associate anemia . Previous study epoetin alfa suggest achieve high hemoglobin level may improve quality life help patient live longer.This randomize , double-blind , placebo-controlled multi-center study evaluate effect treatment epoetin alfa maintain hemoglobin level 12 14 g/dL determine impact survival quality life , addition investigate possible role epoetin alfa may tumor response chemotherapy . During double-blind portion study , patient receive 12 month treatment epoetin alfa placebo . Thereafter , follow-up evaluation occur every 3 month 75 % patient die . Effectiveness determine record number patient survive 12 month , change hemoglobin start study study completion , response chemotherapy quality life . Safety evaluation ( incidence adverse event , physical examination clinical laboratory test ) perform throughout study . The study hypothesis maintain hemoglobin range 12 14 g/dL would improve 12-month survival quality life patient metastatic breast cancer receive chemotherapy . Since time study originally design , prescribe information epoetin alfa change . Current use epoetin alfa follow prescribe information . Patients receive epoetin alfa injection ( 40,000 unit ) skin per week 12 month match placebo . Dosage adjust ( 60,000 unit ) ( 75 % last dose administer ) need maintain hemoglobin level 12 14 g/dL .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Female patient &gt; = 18 year age confirm diagnosis metastatic breast cancer predict start chemotherapy first time Weight &gt; = 40 kg ( 88 lb ) Postmenopausal least 1 year , surgically sterile practice effective method birth control negative serum pregnancy test start study Must sign informed consent Clinically significant lung , heart , hormone , neurological , gastrointestinal , urinary tract reproductive system disease Receiving dose intensification chemotherapy bone marrow stem cell transplantation Cancer brain brain/spinal cord disease Locally advance inflammatory breast cancer symptom breast cancer Active second primary cancer document history cancer within last 3 year Anemia cause cancer radiotherapy/chemotherapy History stoke , clots lung legs blood clot disorder Uncontrolled high blood pressure Untreated folate Vitamin B12 deficiency Treatment epoetin alfa form erythropoietin within last 4 week Known hypersensitivity epoetin alfa component Pregnant breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Breast Tumor</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Women</keyword>
	<keyword>Female</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Hemoglobin</keyword>
	<keyword>Survival</keyword>
	<keyword>Epoetin</keyword>
	<keyword>Epoetin alfa</keyword>
	<keyword>erythropoietin</keyword>
</DOC>